Engineered nano-based device for glioblastoma multiforme therapy
Welcome to the website of the Nano4Glio project.
M-ERA.NET Call 2021
This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 958174; and from national funds through the Foundation for Science and Technology (FCT) (Portugal) (M-ERA-NET3/0001/2021) and The Research Council of Norway (project number 337544).
Glioblastoma (GBM) is an aggressive brain tumor that is incurable due to drugs’ low bioavailability in the brain and resistance mechanisms. Other limitations, such as high toxicity, reenforce the need for new therapies.
Nano4Glio will develop an implantable device composed of a biodegradable hydrogel incorporating drug-loaded nanoparticles (NPs) for GBM continuous treatment.
This project will deliver a suitable approach to improve GBM therapeutic efficacy, allowing for a continuous and enhanced therapy, without the need for daily administration, while overcoming resistance. Thus, Nano4Glio will deliver a pioneering approach that will be able to overcome the limitations of current therapies.